(Q50491342)

14 March 2018

title

Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial (English)

1 reference

14 March 2018

author name string

Christopher Horvath

1

1 reference

14 March 2018

Laura Andrews

2

1 reference

14 March 2018

Andreas Baumann

3

1 reference

14 March 2018

Lauren Black

4

1 reference

14 March 2018

Diann Blanset

5

1 reference

14 March 2018

Joy Cavagnaro

6

1 reference

14 March 2018

Kenneth L Hastings

7

1 reference

14 March 2018

David L Hutto

8

1 reference

14 March 2018

Timothy K MacLachlan

9

1 reference

14 March 2018

Mark Milton

10

1 reference

14 March 2018

Theresa Reynolds

11

1 reference

14 March 2018

Stan Roberts

12

1 reference

14 March 2018

Mark Rogge

13

1 reference

14 March 2018

Jennifer Sims

14

1 reference

14 March 2018

George Treacy

15

1 reference

14 March 2018

Garvin Warner

16

1 reference

14 March 2018

James D Green

17

1 reference

14 March 2018

publication date

31 August 2012

1 reference

14 March 2018

Nature Reviews Immunology

published in

1 reference

14 March 2018

volume

12

1 reference

14 March 2018

issue

10

1 reference

14 March 2018

page(s)

740; author reply 740

1 reference

14 March 2018

cites work

Bacterial superantigens

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

The storm has cleared: lessons from the CD28 superagonist TGN1412 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(-/-)gammac(-/-) mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI3192-C1

Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22941443

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22941443

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRI3192-C1

1 reference

14 March 2018

1 reference

14 March 2018